SCHEMBL682786

SCHEMBL682786

CC(CN(C)C)n1c(Cc2ccccc2)nc2c1c(=O)n(C)c(=O)n2C

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 2/20 0.65
KMT2A Q03164 3/20 0.62
MEN1 O00255 2/20 0.62
NPC1 O15118 1/20 0.62
ATM Q13315 1/20 0.62
LMNA P02545 8/20 0.56
ALDH1A1 P00352 4/20 0.56
MAPT P10636 1/20 0.56
SMN1; SMN2 Q16637 6/20 0.54
HTT P42858 5/20 0.54
CASP1 P29466 2/20 0.54
CASP7 P55210 1/20 0.54
HSD17B10 Q99714 1/20 0.54
TSHR P16473 8/20 0.53
NPSR1 Q6W5P4 4/20 0.53
JAK2 O60674 1/20 0.51
USP2 O75604 1/20 0.50
MAPK1 P28482 1/20 0.49
GLA P06280 1/20 0.49
MAOB P27338 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8373801 0.85 RXFP1 (0.72) RXFP1KMT2AMEN1NPC1ATM
SCHEMBL3099603 0.79 RXFP1 (1.00) RXFP1KMT2ALMNASMN1; SMN2HSD17B10
SCHEMBL8683232 0.78 RXFP1 (0.58) RXFP1KMT2AMEN1NPC1ATM
SCHEMBL683954 0.76 RXFP1 (0.66) RXFP1KMT2AMEN1LMNAALDH1A1
SCHEMBL29376542 0.73 RXFP1 (0.72) RXFP1KMT2AMEN1LMNAALDH1A1
SCHEMBL8373802 0.73 RXFP1 (0.72) RXFP1KMT2AMEN1LMNAALDH1A1
SCHEMBL684310 0.72 RXFP1 (0.66) RXFP1KMT2AMEN1LMNAALDH1A1
SCHEMBL14028471 0.71 RXFP1 (0.77) RXFP1KMT2ALMNATSHRMAOB
SCHEMBL29377329 0.70 RXFP1 (0.66) RXFP1KMT2AMEN1LMNAALDH1A1
SCHEMBL19829270 0.70 TSHR (0.64) RXFP1KMT2AMEN1LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF RXFP1 211/4885KMT2A 1893/4885MEN1 1910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.